Real-World Evidence of the Effect of Adjunctive Semaglutide on Weight Change, Glycemic Control, and Metabolic Dysfunction-Associated Steatotic Liver Disease in People with Type 1 Diabetes
Semaglutide in T1D was safe and well-tolerated and led to significant weight loss, improved glycemic control, and amelioration of MASLD.
Authors
- Eveline Dirinck (ORCID: https://orcid.org/0000-0002-5211-2210)
- Jonathan Mertens (ORCID: https://orcid.org/0000-0002-4822-4113)
- Christophe De Block (ORCID: https://orcid.org/0000-0002-0679-3203)
- Sven Francque (ORCID: https://orcid.org/0000-0002-7527-4714)
- Hennah T. De Winter
Institutions
- University of Antwerp (BE)
- Antwerp University Hospital (BE)
Publication Details
- Journal
- Diabetes Technology & Therapeutics
- Published
- 2025-07-24
- DOI
- https://doi.org/10.1177/15209156251362497
- Citations
- 3
- Primary Topic
- Diabetes Management and Research
- Type
- article
- Field-Weighted Citation Impact
- 3.88